Veliparib is a new oral drug that is being developed for patients with HER2- breast cancer that is advanced and cannot be removed completely through surgery. The drug acts by targeting specific enzymes involved in the repair of damaged DNA that helps the body to kill cancer cells while allowing ordinary cells to survive. Veliparib is being developed to be used in combination with the chemotherapy drugs paclitaxel and carboplatin. If licenced, this combination will offer an additional treatment option for patients with HER2- metastatic or locally advanced unresectable BRCA-associated breast cancer.
ALXN1210 is an antibody under development that prevents the destruction of red blood cells (RBCs). The drug is administered by intravenous injection that requires fewer dosing regimen compared to current treatment option. If ALXN1210 is licensed for use in the UK, it could represent an additional treatment option for patients with paroxysmal nocturnal haemoglobinuria.